Attention Members and Providers: MHS wants you to know about a recent drug recall
Date: 06/19/17
IMPORTANT ELIQUIS (APIXABAN) 5 MG TABLETS RECALL NOTICE
On June 13, 2017, the U.S. Food and Drug Administration (FDA) announced that Bristol-Myers Squibb Company (NYSE: BMY) is voluntarily recalling one lot (#HN0063) of Eliquis 5 mg tablets to the consumer level. Bristol-Myers Squibb is taking this precautionary measure based on a customer complaint that a bottle labeled as Eliquis 5 mg was found to contain Eliquis 2.5 mg tablets.
The FDA press release states the following:
- Eliquis 5 mg tablets are packaged in 60-count bottles, Lot HN0063, Exp 09/2019, NDC 00003-0894-21
- This lot was distributed nationwide in the U.S. to wholesalers and retail pharmacies in February 2017.
- To date, there have not been any reports of injuries or illnesses related to this issue.
- Bristol-Myers Squibb has notified wholesalers and pharmacies to arrange for return and replacement of any recalled product.
Bristol-Myers Squibb does not encourage that consumers discontinue use of the recalled product. Bristol-Myers Squibb is notifying its distributors and customers including doctors, pharmacies, wholesalers and other customers in the supply chain by letter, fax, email and phone calls. Consumers may return the unused portion of the medication to the pharmacy from which it was obtained. Bristol-Myers Squibb has not yet addressed how it will return and/or reimburse for the recalled products. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug productThe recall affects one lot of Eliquis 5 mg currently on the market. This includes lot number HN0063. This lot expires September 2019.